EU High Court Clarifies Generics Question In J&J Case

Law360, New York (June 18, 2009, 12:00 AM EDT) -- Europe's highest court has ruled that drugmaker Generics UK Ltd. should not be permitted to market a generic version of Alzheimer's disease treatment Reminyl — a victory for Johnson & Johnson and Shire PLC that settles a key question over drug product exclusivity in the European Union.

Generics UK had asked the European Court of Justice, Europe's highest court, to review a UK regulator's refusal to grant marketing authorization to the company for a generic version of the Alzheimer's drug Reminyl.

Reminyl contains the active ingredient...
To view the full article, register now.